tiprankstipranks
Trending News
More News >
AstraZeneca PLC (GB:AZN)
LSE:AZN
UK Market

AstraZeneca (AZN) Share Forecast & Price Target

Compare
899 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
11 Buy
2 Hold
1 Sell
Based on 14 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

15,728.61p
▲(3.12% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 15,728.61p with a high forecast of 18,400.00p and a low forecast of 11,300.00p. The average price target represents a 3.12% change from the last price of 15,252.00p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10222":"10,222p","18401":"18,401p","12266.75":"12,266.8p","14311.5":"14,311.5p","16356.25":"16,356.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15728.607085416668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">16K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10222,12266.75,14311.5,16356.25,18401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15252,15494.153846153846,15736.307692307691,15978.461538461539,16220.615384615385,16462.76923076923,16704.923076923078,16947.076923076922,17189.23076923077,17431.384615384617,17673.53846153846,17915.69230769231,18157.846153846152,{"y":18400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15252,15288.66208349359,15325.32416698718,15361.98625048077,15398.648333974359,15435.31041746795,15471.97250096154,15508.634584455129,15545.296667948718,15581.95875144231,15618.620834935899,15655.282918429488,15691.945001923079,{"y":15728.607085416668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15252,14948,14644,14340,14036,13732,13428,13124,12820,12516,12212,11908,11604,{"y":11300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11762.989,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11171.301,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10426.285,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10392.868,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10223.814,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10913.788,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11728.389,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12308.375,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12342.026,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13694.008,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13648.479,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13895.914,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15252,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target18,400pAverage Price Target15,729pLowest Price Target11,300p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:AZN
J.P. Morgan
J.P. Morgan
15,110p
Buy
-0.93%
Downside
Reiterated
03/02/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Morgan Stanley Analyst forecast on GB:AZN
Morgan Stanley
Morgan Stanley
8,131.34p16,337.29p
Buy
7.12%
Upside
Reiterated
03/02/26
AstraZeneca price target raised to $219 from $109 at Morgan StanleyAstraZeneca price target raised to $219 from $109 at Morgan Stanley
UBS
16,300p17,600p
Buy
15.39%
Upside
Reiterated
02/25/26
UBS Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on GB:AZN
Berenberg Bank
Berenberg Bank
16,000p17,000p
Buy
11.46%
Upside
Reiterated
02/18/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Deutsche Bank  Analyst forecast on GB:AZN
Deutsche Bank
Deutsche Bank
11,500p
Sell
-24.60%
Downside
Reiterated
02/16/26
Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on GB:AZN
DZ BANK AG
DZ BANK AG
Hold
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Goldman Sachs Analyst forecast on GB:AZN
Goldman Sachs
Goldman Sachs
16,389p16,496p
Buy
8.16%
Upside
Reiterated
02/11/26
Goldman Sachs Keeps Their Buy Rating on AstraZeneca (AZN)
Citi
17,000p
Buy
11.46%
Upside
Reiterated
02/11/26
AstraZeneca (AZN) Gets a Buy from Citi
Bernstein Analyst forecast on GB:AZN
Bernstein
Bernstein
184p18,400p
Buy
20.64%
Upside
Assigned
02/10/26
AstraZeneca (AZN) Gets a Buy from Bernstein
Bank of America Securities Analyst forecast on GB:AZN
Bank of America Securities
Bank of America Securities
16,500p
Buy
8.18%
Upside
Reiterated
02/10/26
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
Barclays
16,500p
Buy
8.18%
Upside
Reiterated
02/10/26
Barclays Remains a Buy on AstraZeneca (AZN)
Kepler Capital  Analyst forecast on GB:AZN
Kepler Capital
Kepler Capital
11,300p
Hold
-25.91%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Jefferies
15,000p
Buy
-1.65%
Downside
Reiterated
02/10/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
Shore Capital Analyst forecast on GB:AZN
Unknown Analyst
Shore Capital
Not Ranked
Shore Capital
Buy
Reiterated
01/16/26
Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)
HSBC Analyst forecast on GB:AZN
Unknown Analyst
HSBC
Not Ranked
HSBC
10,921.36p12,308.91p
Buy
-19.30%
Downside
Reiterated
12/02/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:AZN
J.P. Morgan
J.P. Morgan
15,110p
Buy
-0.93%
Downside
Reiterated
03/02/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Morgan Stanley Analyst forecast on GB:AZN
Morgan Stanley
Morgan Stanley
8,131.34p16,337.29p
Buy
7.12%
Upside
Reiterated
03/02/26
AstraZeneca price target raised to $219 from $109 at Morgan StanleyAstraZeneca price target raised to $219 from $109 at Morgan Stanley
UBS
16,300p17,600p
Buy
15.39%
Upside
Reiterated
02/25/26
UBS Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on GB:AZN
Berenberg Bank
Berenberg Bank
16,000p17,000p
Buy
11.46%
Upside
Reiterated
02/18/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Deutsche Bank  Analyst forecast on GB:AZN
Deutsche Bank
Deutsche Bank
11,500p
Sell
-24.60%
Downside
Reiterated
02/16/26
Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on GB:AZN
DZ BANK AG
DZ BANK AG
Hold
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Goldman Sachs Analyst forecast on GB:AZN
Goldman Sachs
Goldman Sachs
16,389p16,496p
Buy
8.16%
Upside
Reiterated
02/11/26
Goldman Sachs Keeps Their Buy Rating on AstraZeneca (AZN)
Citi
17,000p
Buy
11.46%
Upside
Reiterated
02/11/26
AstraZeneca (AZN) Gets a Buy from Citi
Bernstein Analyst forecast on GB:AZN
Bernstein
Bernstein
184p18,400p
Buy
20.64%
Upside
Assigned
02/10/26
AstraZeneca (AZN) Gets a Buy from Bernstein
Bank of America Securities Analyst forecast on GB:AZN
Bank of America Securities
Bank of America Securities
16,500p
Buy
8.18%
Upside
Reiterated
02/10/26
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
Barclays
16,500p
Buy
8.18%
Upside
Reiterated
02/10/26
Barclays Remains a Buy on AstraZeneca (AZN)
Kepler Capital  Analyst forecast on GB:AZN
Kepler Capital
Kepler Capital
11,300p
Hold
-25.91%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Jefferies
15,000p
Buy
-1.65%
Downside
Reiterated
02/10/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
Shore Capital Analyst forecast on GB:AZN
Unknown Analyst
Shore Capital
Not Ranked
Shore Capital
Buy
Reiterated
01/16/26
Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)
HSBC Analyst forecast on GB:AZN
Unknown Analyst
HSBC
Not Ranked
HSBC
10,921.36p12,308.91p
Buy
-19.30%
Downside
Reiterated
12/02/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
xxx
Success Rate
15/21 ratings generated profit
71%
Average Return
+4.51%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +4.51% per trade.
1 Year
Success Rate
36/38 ratings generated profit
95%
Average Return
+19.71%
a rating ―
Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +19.71% per trade.
2 Years
xxx
Success Rate
19/19 ratings generated profit
100%
Average Return
+33.71%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
1
0
0
0
0
Buy
36
34
29
29
24
Hold
6
2
1
2
2
Sell
5
6
5
5
4
Strong Sell
0
0
0
0
0
total
48
42
35
36
30
In the current month, AZN has received 24 Buy Ratings, 2 Hold Ratings, and 4 Sell Ratings. AZN average Analyst price target in the past 3 months is 15,728.61.
Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.86p with a range of 1.76p to 2.06p. The previous quarter’s EPS was 1.58p. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s earnings estimate for AZN is 1.86p with a range of 1.76p to 2.06p. The previous quarter’s EPS was 1.58p. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 10.94B with a range of 10.66B to 11.38B. The previous quarter’s sales results were 11.66B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s sales forecast for AZN is 10.94B with a range of 10.66B to 11.38B. The previous quarter’s sales results were 11.66B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 15,728.61.
    What is GB:AZN’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 3.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 2 hold ratings and 1 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 15,728.61. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 18,400.00p ,and the lowest forecast is 11,300.00p. The average share price target represents 3.12% Increase from the current price of 15,252p.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.